FLT3 and acute myeloid leukemia: With respect to patients with FLT3-mutated AML, the MORPHO trial demonstrated that patients with undetectable MRD status at the time of transplant did well with less intensive conditioning regimens, while those with detectable MRD benefited from more intensive regimens [75].